AbbVie (NYSE:ABBV) Trading Up 1.2% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shares were up 1.2% during mid-day trading on Friday . The company traded as high as $230.47 and last traded at $227.6840. Approximately 6,093,202 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 6,862,657 shares. The stock had previously closed at $224.94.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

Analyst Ratings Changes

Several analysts recently weighed in on the company. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Thursday, April 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. Guggenheim restated a “buy” rating and issued a $249.00 price target on shares of AbbVie in a research note on Friday, May 1st. Piper Sandler raised their price target on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group raised their price target on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Stock Up 1.2%

The firm has a fifty day moving average price of $209.85 and a two-hundred day moving average price of $219.36. The stock has a market capitalization of $402.27 billion, a P/E ratio of 112.16, a P/E/G ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period last year, the firm posted $2.46 earnings per share. AbbVie’s revenue was up 12.4% compared to the same quarter last year. Sell-side analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AbbVie

Institutional investors have recently modified their holdings of the business. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter valued at $26,000. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the fourth quarter worth about $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.3% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Westend Capital Management LLC purchased a new position in AbbVie in the fourth quarter worth about $29,000. Finally, IFC & Insurance Marketing Inc. purchased a new position in AbbVie in the fourth quarter worth about $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.